MRNA Stock Moderna, Inc.
BUY US · NasdaqGSAnalyst upgrade, breakout momentum, and strategy reset support a rebound if execution stabilizes.
Future value: $135.84 (-31.69%) · 6-12 months · analyst consensus
Signal breakdown
- ▸William Blair upgrade and strong momentum after new 52-week high.
- ▸Above 50-day MA (+14.38%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (76% of range) — strength
- ▾Trading above its price target — limited upside
Is MRNA a buy right now?
Trend: MRNA is trading above the 50-day average (+14.37%), RSI 66 — neutral momentum, with a 3-month return of +256.33%.
Valuation & quality: Moderna, Inc. trades on forward P/E -43.5, price-to-book 11.74; fundamentals show net margin -141.4%, return on equity -39.0%, revenue growth 2.1% year on year.
Analyst consensus: 19 analysts have a mean 12-month price target of $138.37 (-30.4% vs the last close; range $45.00 – $251.00), consensus rating “hold”.
Our screen: BUY (score 3) — Analyst upgrade, breakout momentum, and strategy reset support a rebound if execution stabilizes.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -5.20% | -9.60% | +2.70% | +48.40% | -21.70% | +156.00% | +37.20% | +3.30% |
Fundamentals
Analyst price target
Technical signals
About Moderna, Inc.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
Sector: Healthcare · Industry: Biotechnology · United States · 4,700 employees · Website
Related Biotech picks
Browse: all US stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.